Drug Response Testing and Repurposing Using Glioblastoma Organoid
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorChungnam National University Hospital
About this trial
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Eligibility criteria
Qualifiers
primary or recurrent glioblastoma
patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
sufficient tumor sample is available for organoid culture
Disqualifiers
patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery
failed to obtain MRI scan after CCRT
patients refusal
Trial design
Treatments tested in this trial
- Organoid-based drug sensitivity test
Treatment groups
150 Participants
are divided into 1 treatment groupLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Chungnam National University HospitalRecruiting35015, Daejeon, Chungcheongnam-doSouth Korea
Sponsors and collaborators
Chungnam National University Hospital
Lead sponsor
Korea Advanced Institute of Science and Technology
Collaborator
Keimyung University Dongsan Medical Center
Collaborator
Soonchunhyang University Hospital
Collaborator
Dong-A University Hospital
Collaborator
Yeungnam University Hospital
Collaborator
Source ClinicalTrials.gov